Copyright
©The Author(s) 2024.
World J Virol. Jun 25, 2024; 13(2): 92521
Published online Jun 25, 2024. doi: 10.5501/wjv.v13.i2.92521
Published online Jun 25, 2024. doi: 10.5501/wjv.v13.i2.92521
Figure 1 Blocking of granulocyte macrophage-colony stimulating factor with monoclonal antibody to cease inflammatory responses associated with proinflammatory cells, i.
e., M1 macrophages. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; GM-CSF: Granulocyte macrophage-colony stimulating factor; mAb: Monoclonal antibody.
- Citation: Velikova T, Valkov H, Aleksandrova A, Peshevska-Sekulovska M, Sekulovski M, Shumnalieva R. Harnessing immunity: Immunomodulatory therapies in COVID-19. World J Virol 2024; 13(2): 92521
- URL: https://www.wjgnet.com/2220-3249/full/v13/i2/92521.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i2.92521